Cash from Operations (Annual) Chart

View Cash from Operations (Annual) for VRTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Annual) Chart
Start Trial

Historical Cash from Operations (Annual) Data

View and export this data back to 1991. Start Trial.
Date Value
December 31, 2025 3.631B
December 31, 2024 -492.60M
December 31, 2023 3.537B
December 31, 2022 4.130B
December 31, 2021 2.644B
December 31, 2020 3.254B
December 31, 2019 1.569B
December 31, 2018 1.270B
December 31, 2017 844.94M
December 31, 2016 236.10M
December 31, 2015 -365.43M
December 31, 2014 -513.20M
December 31, 2013 -51.57M
December 31, 2012 267.84M
December 31, 2011 143.74M
December 31, 2010 -635.44M
December 31, 2009 -427.59M
December 31, 2008 -226.48M
Date Value
December 31, 2007 -252.48M
December 31, 2006 -22.48M
December 31, 2005 -172.07M
December 31, 2004 -142.16M
December 31, 2003 -167.62M
December 31, 2002 -79.54M
December 31, 2001 -8.074M
December 31, 2000 -16.64M
December 31, 1999 -31.81M
December 31, 1998 -31.06M
December 31, 1997 -9.362M
December 31, 1996 -40.25M
December 31, 1995 -15.95M
December 31, 1994 -14.68M
December 31, 1993 8.632M
December 31, 1992 -5.327M
December 31, 1991 -2.524M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Annual) Range, Past 5 Years

View Cash from Operations (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Annual) Benchmarks

View Cash from Operations (Annual) Benchmarks
Start Trial
Gilead Sciences, Inc. 10.02B
Alnylam Pharmaceuticals, Inc. 524.08M
Sionna Therapeutics, Inc. -66.30M
Regeneron Pharmaceuticals, Inc. 4.979B
Biogen, Inc. 2.205B